acute myeloid leukemia Clinical Trials and Research
Also known as: acute myelogenous leukemia, aml, acute nonlymphocytic leukemia, myeloid leukemia, acute granulocytic leukemia · ICD-10: C92.0
Acute myeloid leukemia (AML) is a rapidly progressing cancer affecting blood and bone marrow. Clinical trial research focuses on developing new targeted therapies, immunotherapies, and improving existing treatments to enhance patient outcomes. Find a Trial helps patients search for active studies.
Search acute myeloid leukemia trials →
Common questions about acute myeloid leukemia clinical trials
What are the different phases of AML clinical trials?
Clinical trials typically progress through phases 1, 2, and 3. Phase 1 studies assess safety, phase 2 evaluates effectiveness, and phase 3 compares new treatments to standard ones, as detailed on ClinicalTrials.gov.
What new treatments are being studied for acute myeloid leukemia?
Current research for AML explores targeted therapies that block specific cancer pathways, immunotherapies that harness the body's immune system, and novel chemotherapy combinations. Data from NIH RePORTER and ClinicalTrials.gov show these areas are active.
What types of interventions are common in AML clinical trials?
Common interventions include new chemotherapy regimens, targeted drugs, stem cell transplants, and immunotherapies. Studies often compare these new approaches against standard care to assess their safety and effectiveness, according to ClinicalTrials.gov.
Do participants have to pay to join an AML clinical trial?
Generally, study-related medical costs, such as investigational drugs and procedures, are covered by the trial sponsor. However, routine care costs and travel expenses may not be, as outlined in study protocols on ClinicalTrials.gov.
Are there specific biomarkers important in AML clinical trials?
Yes, genetic mutations like FLT3, IDH1/2, and NPM1 are important biomarkers in AML. Clinical trials often use these to identify patients who might respond best to targeted therapies, as evidenced by research on NIH RePORTER.
What are common reasons someone might be excluded from an AML clinical trial?
Common exclusion criteria include uncontrolled infections, significant heart or kidney problems, or other active cancers. These are in place to protect patient safety and ensure reliable study results, as seen on ClinicalTrials.gov.
What are the potential benefits and risks of participating in an AML clinical trial?
Potential benefits include access to new treatments before they are widely available, while risks can include unexpected side effects or the treatment not being effective. These are carefully explained during the informed consent process, per ClinicalTrials.gov.
How to find a acute myeloid leukemia trial that fits you
- Describe your acute myeloid leukemia situation in detail — stage if applicable, prior treatments, age, and other relevant conditions.
- Use the location filter (worldwide, US, US & Canada, Europe) to narrow to trials near you.
- Review each trial's eligibility criteria carefully. Save 2–5 candidates with their NCT numbers.
- Discuss with your treating clinician before contacting the research site.
Browse all acute myeloid leukemia trials →